Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.

Tomás José González-LópezBlanca Sánchez-GonzálezIsidro JarqueSilvia BernatFernando Fernández-FuertesIsabel CaparrósInmaculada SotoAngeles Fernández-RodríguezEstefanía BolañosGloria Pérez-RusCristina PascualJosé Angel Hernández-RivasElsa López-AnsoarMarta Gómez-NuñezVioleta Martínez-RoblesPavel OliveraMaria Yera CoboMaría Jesús PeñarrubiaCarmen Fernández-MiñanoErik de CaboMaría Paz Martínez BadasGermán PerdomoLuis Javier García-Frade

Published in: European journal of haematology (2020)

Eltrombopag showed efficacy and safety in ITP patients aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD-ITP were poor. A relatively high number of deaths were observed.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis